ZYBERNO
Stock Report
Updated Sep 1, 2026

ALTIMMUNE, INC. (ALT)

Healthcare • NASDAQ

$3.11

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
28.0/100
POOR BUSINESS
ALTIMMUNE, INC. (ALT) scores 28/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-31.4%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.08x)
Operating Margin (Operational Efficiency):CRITICAL (-501,125.0%)
Return on Capital (Capital Efficiency):CRITICAL (-16.1%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

ALTIMMUNE, INC. (ALT) stock report — Zyberno Score 28/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:3.11
Market Cap:$576.73M

Valuation Multiples (3)

P/B Ratio:1.22x
P/S Ratio:28,836.50x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$570.08M

Price Action & Momentum (3)

Momentum Percentile:21 / 100
% of 52-Week High:48.3%
B. Profitability Assessment

Return Metrics (5)

ROA:-27.0%
Reinvestment Rate:0.1%
Fundamental Growth Rate (g):0.0%

Margin Analysis (3)

Operating Margin Ttm:-501,125.0%
Net Margin Ttm:-458,800.0%
Ebitda Margin:-500,595.0%

TTM Performance (2)

Operating Margin Ttm:-501,125.0%
Net Margin Ttm:-458,800.0%

Yield Metrics (2)

Earnings Yield:-$24.76
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:35.6%
Latest Earnings Filed:2026-08-12

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-31.2%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:26.78x
Quick Ratio:26.78x
Cash Ratio:5.04x

Leverage Analysis (3)

Debt To Equity Ttm:0.08x
Debt-to-Equity Ratio:0.08x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-26.72x
Times Interest Earned:-26.72

Capital Structure (4)

Working Capital:322,314,000.00
Cash And Cash Equivalents:63,008,000.00
Long Term Debt:$34.74M
Net Debt:-$6.66M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $20.00K
Linear Growth: -31.2%
📊 Click to view full ALT Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$100.23M

Bottom Line Performance (3)

-$91.76M
Income Before Tax:-$91.76M
Ebitda Ttm:-100,119,000.00

Operating Expenses (5)

Operating Expenses:100,256,000.00
R And D Expense:68,216,000.00
Sga Expense:32,040,000.00
Income Tax Expense:-$681.00K
Interest Expense:3,536,000.00

Expense Ratios (3)

R And D To Revenue Percentage:1,364,320.0%
Sga To Revenue Percentage:640,800.0%
Ebitda Margin:-500,595.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$527.21M
Current Assets:$334.82M
Ppe Net:60,000.00
Goodwill:0.00
Intangible Assets:$12.42M

Liability Structure (4)

Total Liabilities:53,004,000.00
Current Liabilities:12,501,000.00
Long Term Debt:$34.74M
Short Term Debt:$21.61M

Equity & Capital (3)

Equity:$474.21M
Retained Earnings:-$694.87M
Common Stock:400,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:1,272,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:2,788,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$71.64M-$67.55M

Investment Activities (1)

Investing Cash Flow:-$3.69M

Financing Activities (3)

Financing Cash Flow:$78.47M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:8,742,000.00
Long Term Debt Issuance:$2.50M
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:106,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.77
-$0.77
Earnings Per Share Ttm:-$0.49

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.00
Operating Cash Flow Per Share:-$0.36

Book Value & Capital (2)

Book Value Per Share:$2.56
Cash Per Share:0.34

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.00x
Working Capital Turnover Ttm:0.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:23,214.00
Cash Conversion Cycle:-25,212.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:0.1%
Fundamental Growth Rate (g):0.0%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-31.2%

Other Growth Rates (1)

Book Value Growth Rate (Linear):9.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:ALT
Company Name:ALTIMMUNE, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:185.44M
Shares Outstanding Basic:185.44M
Shares Outstanding Diluted:185.44M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 23:30:04 UTC
Data Timestamp:2026-09-01T23:30:04.732401
Scroll to Top